Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delitinib plus Toripalimab in Advanced Solid Tumors
CTR20191618Phase 2Terminated
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ximetinib, toripalimab in Nonhematologic neoplasms, nasopharyngeal carcinoma (NPC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma (HCC), sponsored by Shanghai Institute of Materia Medica. Started Aug 2019; status: terminated.
02
Drugs
ximetinibtoripalimab
03
Conditions
Nonhematologic neoplasmsnasopharyngeal carcinoma (NPC)gastric adenocarcinomagastroesophageal junction adenocarcinomahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20191618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191618.